KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 83 filers reported holding KEROS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,795 | -88.0% | 12,572 | -84.8% | 0.00% | -100.0% |
| Q2 2023 | $3,330,560 | -10.8% | 82,891 | -5.2% | 0.00% | 0.0% |
| Q1 2023 | $3,731,809 | +578.7% | 87,396 | +663.3% | 0.00% | – |
| Q4 2022 | $549,829 | +81.5% | 11,450 | +42.3% | 0.00% | – |
| Q3 2022 | $303,000 | +6.3% | 8,044 | -21.7% | 0.00% | – |
| Q2 2022 | $285,000 | -48.4% | 10,275 | +1.3% | 0.00% | – |
| Q1 2022 | $552,000 | -15.3% | 10,140 | -9.0% | 0.00% | – |
| Q4 2021 | $652,000 | +52.7% | 11,146 | +3.4% | 0.00% | – |
| Q3 2021 | $427,000 | -9.0% | 10,777 | -2.6% | 0.00% | – |
| Q2 2021 | $469,000 | -20.9% | 11,064 | +14.6% | 0.00% | – |
| Q1 2021 | $593,000 | -19.4% | 9,652 | -7.6% | 0.00% | – |
| Q4 2020 | $736,000 | +394.0% | 10,444 | +171.1% | 0.00% | – |
| Q3 2020 | $149,000 | +12.9% | 3,852 | +9.6% | 0.00% | – |
| Q2 2020 | $132,000 | – | 3,516 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |